Atossa Therapeutics Inc (NASDAQ:ATOS)
| 2.43 Delayed Data As of Sep 18 |  +0.11 / +4.74%Today’s Change | 0.76 Today|||52-Week Range 5.08 | +54.78% Year-to-Date |
Latest ATOS News | Press Releases
| Atossa's COVID-19 nasal spray receives second positive safety review Sep 17 / Seeking Alpha - Paid Partner Content | Atossa files for $100M mixed shelf Sep 02 / Seeking Alpha - Paid Partner Content |
| SRNE, IMGN among premarket gainers Sep 17 / Seeking Alpha - Paid Partner Content | WDAY, ULTA among premarket gainers. Aug 28 / Seeking Alpha - Paid Partner Content |
Today’s Trading
| Previous close | 2.32 |
| Today’s open | 2.34 |
| Day’s range | 2.33 - 2.54 |
| Volume | 8,247 |
| Average volume (3 months) | 824,977 |
| Market cap | $25.3M |
Data as of 3:55pm ET, 09/18/2020
Growth & Valuation
| Earnings growth (last year) | +63.14% |
| Earnings growth (this year) | +28.57% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -- |
| P/E ratio | NM |
| Price/Sales | -- |
| Price/Book | 1.78 |
Competitors
Data as of 3:54pm ET, 09/18/2020
Financials
| Next reporting date | November 17, 2020 |
| EPS forecast (this quarter) | -$0.35 |
| Annual revenue (last year) | $0.00 |
| Annual profit (last year) | -$17.2M |
| Net profit margin | -- |
Profile
Sector Health Technology |
Industry Medical Specialties |
No executives to display |
Corporate headquarters Seattle, Washington |
Forecasts
